{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:32:17Z","timestamp":1790343137050,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"am","delay-in-days":267,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA269607"],"award-info":[{"award-number":["RO1CA269607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117276","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T23:10:27Z","timestamp":1755904227000},"page":"117276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatment"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-3694","authenticated-orcid":false,"given":"Md Ataur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Yadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meser M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0005","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2025.117276_b0010","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","article-title":"World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review","volume":"8","author":"Berger","year":"2022","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117276_b0015","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014A literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-025-03419-y","article-title":"Application of artificial intelligence in forecasting survival in high-grade glioma: systematic review and meta-analysis involving 79,638 participants","volume":"48","author":"Mohammadzadeh","year":"2025","journal-title":"Neurosurg. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117276_b0025","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.3390\/ijms25063217","article-title":"A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance","volume":"25","author":"Karve","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117276_b0030","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.7150\/thno.82005","article-title":"Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment","volume":"13","author":"Iturrioz-Rodr\u00edguez","year":"2023","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bcp.2025.117276_b0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/cancers17040701","article-title":"Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities","volume":"17","author":"Rahman","year":"2025","journal-title":"Cancers"},{"issue":"45","key":"10.1016\/j.bcp.2025.117276_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202270241","article-title":"Micro\u2010nanocarriers based drug delivery technology for blood\u2010brain barrier crossing and brain tumor targeting therapy","volume":"18","author":"Wang","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.bcp.2025.117276_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1519479","article-title":"Applications of polymeric nanoparticles in drug delivery for glioblastoma","volume":"15","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117276_b0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/neuroglia6020022","article-title":"The Synergistic Roles of Glial Cells and Non-Coding RNAs in the Pathogenesis of Alzheimer\u2019s Disease and Related Dementias (ADRDs)","volume":"6","author":"Risen","year":"2025","journal-title":"Neuroglia"},{"key":"10.1016\/j.bcp.2025.117276_b0055","article-title":"Central nervous system and immune cells interactions in cancer: unveiling new therapeutic avenues","volume":"16","author":"Wen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117276_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.790976","article-title":"The subventricular zone in glioblastoma: genesis, maintenance, and modeling","volume":"12","author":"Beiriger","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117276_b0065","doi-asserted-by":"crossref","unstructured":"E.R. Matarredona, et al., Neural stem cells of the subventricular zone: from neurogenesis to glioblastoma origin. 2021, Frontiers Media SA. p. 750116.","DOI":"10.3389\/978-2-88971-595-4"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/neuonc\/noae228","article-title":"Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens","volume":"27","author":"Laemmerer","year":"2025","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-025-00597-9","article-title":"Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics","volume":"14","author":"Shou","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41418-024-01259-9","article-title":"Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?","volume":"32","author":"Janic","year":"2025","journal-title":"Cell Death & Differentiation"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0085","doi-asserted-by":"crossref","first-page":"e3998","DOI":"10.1002\/cbf.3998","article-title":"The PI3K\/AKT\/mTOR signaling pathway in breast cancer: review of clinical trials and latest advances","volume":"42","author":"Khorasani","year":"2024","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.bcp.2025.117276_b0090","first-page":"259","article-title":"Unravelling the melanoma maze: biomarkers, diagnosis, and future perspectives in skin cancer management","author":"Page","year":"2025","journal-title":"Adv. Cancer Res. : Exploring Diagnostics Therapeutic Breakthroughs"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0095","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240337","article-title":"Schwann cells in regeneration and cancer: an epithelial\u2013mesenchymal transition perspective","volume":"15","author":"Gracia","year":"2025","journal-title":"Open Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12672-025-02471-w","article-title":"Modulation of the PI3K\/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity","volume":"16","author":"Hedayati","year":"2025","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/10409238.2021.1934811","article-title":"Cancer cells dysregulate PI3K\/AKT\/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses","volume":"56","author":"Cirone","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2025.117276_b0110","article-title":"The potential of exosomes as a new therapeutic strategy for glioblastoma","author":"Silva","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.bcp.2025.117276_b0115","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.3390\/ijms26094104","article-title":"The Role of RAS in CNS tumors: a key player or an overlooked oncogene?","volume":"26","author":"de Souza Barbosa","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117276_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.70071","article-title":"NSD3: a promising target for cancer therapy","volume":"43","author":"Huang","year":"2025","journal-title":"Cell Biochem. Funct."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-024-09996-3","article-title":"Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy","volume":"51","author":"Hasan","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2025.117276_b0130","first-page":"1","article-title":"The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma","author":"Bora Yildiz","year":"2025","journal-title":"Epigenomics"},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0135","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/ijms25052464","article-title":"Use of microRNAs as diagnostic, prognostic, and therapeutic tools for glioblastoma","volume":"25","author":"Valle-Garcia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.62347\/NSXC2205","article-title":"Mechanism analysis and targeted therapy of IDH gene mutation in glioma","volume":"15","author":"Ma","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0145","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3390\/ijms26052108","article-title":"Microenvironmental drivers of glioma progression","volume":"26","author":"Jang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/biomedicines13030759","article-title":"Navigating glioma complexity: the role of abnormal signaling pathways in shaping future therapies","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117276_b0155","article-title":"Metabolomics integrated genomics approach: understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1\/EGFR\/PI3k\/PTEN crosstalk","volume":"14","author":"Kadry","year":"2025","journal-title":"Toxicol. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2025.117276_b0160","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.7150\/ijbs.109803","article-title":"Targeting glycolysis for treatment of breast cancer resistance: current progress and future prospects","volume":"21","author":"Niu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2025.117276_b0165","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/cells14080562","article-title":"Glioblastoma stem cells at the nexus of tumor heterogeneity, immune evasion, and therapeutic resistance","volume":"14","author":"Tang","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cancers17010146","article-title":"Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes","volume":"17","author":"Sipos","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0175","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/cimb46030153","article-title":"Deciphering glioblastoma: fundamental and novel insights into the biology and therapeutic strategies of gliomas","volume":"46","author":"Onciul","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0180","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1227\/01.neu.0000317304.31579.17","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer","year":"2008","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.bcp.2025.117276_b0185","doi-asserted-by":"crossref","first-page":"622","DOI":"10.14482\/sun.40.02.411.999","article-title":"Neurological manifestations of systemic diseases: key aspects for the clinician","volume":"40","author":"Mar\u00edn-Medina","year":"2024","journal-title":"Revista Salud Uninorte"},{"issue":"6","key":"10.1016\/j.bcp.2025.117276_b0190","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/diagnostics14060618","article-title":"Tumor-like lesions in primary angiitis of the central nervous system: the role of magnetic resonance imaging in differential diagnosis","volume":"14","author":"Zedde","year":"2024","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/pharmaceutics16010123","article-title":"Biomolecules to biomarkers? U87MG marker evaluation on the path towards glioblastoma multiforme pathogenesis","volume":"16","author":"Pokorn\u00e1","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-024-04699-y","article-title":"Impact of frailty on survival glioblastoma, IDH-wildtype patients","volume":"169","author":"Hudelist","year":"2024","journal-title":"J. Neurooncol"},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3892\/ol.2025.14989","article-title":"Key genes altered in glioblastoma based on bioinformatics","volume":"29","author":"Al Ghafari","year":"2025","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0210","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acsanm.3c04714","article-title":"Nanotechnology meets stem cell therapy for treating glioblastomas: a review","volume":"7","author":"Ghosh","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"issue":"15","key":"10.1016\/j.bcp.2025.117276_b0215","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/cancers16152638","article-title":"Glioblastoma standard of care: effects on tumor evolution and reverse translation in preclinical models","volume":"16","author":"Rodgers","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0220","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bcp.2025.117276_b0225","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.2147\/IJN.S523008","article-title":"A systematic review of nanoparticle-mediated ferroptosis in glioma therapy","author":"Jing","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0230","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","article-title":"Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy","volume":"12","author":"Lim","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2025.117276_b0235","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/cells13161332","article-title":"Importance of autophagy regulation in glioblastoma with temozolomide resistance","volume":"13","author":"Hwang","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/ph18030282","article-title":"Artificial intelligence models and tools for the assessment of drug\u2013herb interactions","volume":"18","author":"Spanakis","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0250","article-title":"NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma","volume":"6","author":"Minea","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"issue":"9","key":"10.1016\/j.bcp.2025.117276_b0255","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/cancers14092233","article-title":"Senescence is the main trait induced by temozolomide in glioblastoma cells","volume":"14","author":"Beltzig","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117276_b0260","first-page":"1","article-title":"Temozolomide treatment in refractory pituitary adenomas and pituitary carcinomas","author":"Deng","year":"2025","journal-title":"Neuroendocrinology"},{"issue":"19","key":"10.1016\/j.bcp.2025.117276_b0265","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.3390\/cancers16193300","article-title":"Blood\u2013brain barrier conquest in glioblastoma nanomedicine: strategies, clinical advances, and emerging challenges","volume":"16","author":"Duan","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2025.117276_b0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/cancers16020331","article-title":"The versatile attributes of MGMT: its repair mechanism, crosstalk with other DNA repair pathways, and its role in cancer","volume":"16","author":"Fang","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0275","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13402-021-00613-0","article-title":"DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets","volume":"44","author":"Lozinski","year":"2021","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bcp.2025.117276_b0280","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fonc.2019.00485","article-title":"C8-substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0285","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"9","key":"10.1016\/j.bcp.2025.117276_b0290","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3390\/ijms26094394","article-title":"Deficient mismatch repair and microsatellite instability in solid tumors","volume":"26","author":"Awosika","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117276_b0295","first-page":"1","article-title":"Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations","author":"Mandal","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bcp.2025.117276_b0300","article-title":"Mechanisms of the JNK\/p38 MAPK signaling pathway in drug resistance in ovarian cancer","volume":"15","author":"Ma","year":"2025","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/metabo14050249","article-title":"Metabolic roles of HIF1, c-Myc, and p53 in glioma cells","volume":"14","author":"Trejo-Sol\u00eds","year":"2024","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.bcp.2025.117276_b0310","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70474","article-title":"Notch1 and major vault proteins modulate temozolomide resistance in glioblastoma","volume":"29","author":"Tuncer","year":"2025","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.55705\/cmbr.2025.456494.1246","article-title":"Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview Cellular","volume":"5","author":"Reddy","year":"2025","journal-title":"Mol. Biomed. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0320","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12951-025-03247-8","article-title":"The blood\u2013brain barriers: novel nanocarriers for central nervous system diseases","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/JME.JME_155_23","article-title":"Targeting of Nanoparticles towards blood\u2013brain barrier with a potential for the treatment of cerebrovascular disorders: a systematic review (2017\u20132023)","volume":"6","author":"Chakraverty","year":"2025","journal-title":"J. Med. Evid."},{"issue":"2","key":"10.1016\/j.bcp.2025.117276_b0330","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ada85e","article-title":"Transcytosis: an effective mechanism to enhance nanoparticle extravasation and infiltration through biological barriers","volume":"20","author":"Zhang","year":"2025","journal-title":"Biomed. Mater."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/pharmaceutics17010109","article-title":"Targeting brain drug delivery with macromolecules through receptor-mediated transcytosis","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bcp.2025.117276_b0340","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1021\/acschembio.5c00039","article-title":"Optimizing peptide-conjugated lipid nanoparticles for efficient siRNA delivery across the blood\u2013brain barrier and treatment of glioblastoma multiforme","volume":"20","author":"Tong","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117276_b0345","article-title":"Breaking the barrier: nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117276_b0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","article-title":"An update on dual targeting strategy for cancer treatment","volume":"349","author":"Taghipour","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.117276_b0355","first-page":"1","article-title":"Innovative nanodelivery systems for targeted breast cancer therapy: overcoming drug delivery challenges and exploring future perspectives","author":"Su","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2025.117276_b0360","doi-asserted-by":"crossref","first-page":"16050","DOI":"10.1039\/D5RA00948K","article-title":"Magnetic mesoporous silica nanoparticles as advanced polymeric scaffolds for efficient cancer chemotherapy: recent progress and challenges","volume":"15","author":"Payamifar","year":"2025","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.bcp.2025.117276_b0365","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1039\/D3TB02485G","article-title":"Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma","volume":"12","author":"Habeeb","year":"2024","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0370","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12672-025-02413-6","article-title":"RNA-binding proteins and autophagy in lung cancer: mechanistic insights and therapeutic perspectives","volume":"16","author":"Lei","year":"2025","journal-title":"Discov. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117276_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02652-1","article-title":"Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: innovative therapeutic approaches","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2025.117276_b0380","article-title":"Oxidative stress and potential effects of metal nanoparticles: a review of biocompatibility and toxicity concerns","author":"Wang","year":"2024","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.bcp.2025.117276_b0385","first-page":"12","article-title":"The epigenetic mechanisms involved in the treatment resistance of glioblastoma","volume":"8","author":"Shahani","year":"2025","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bcp.2025.117276_b0390","first-page":"1","article-title":"Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment","author":"Zarneshan","year":"2025","journal-title":"Ther. Deliv."},{"issue":"8","key":"10.1016\/j.bcp.2025.117276_b0395","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/biomedicines12081822","article-title":"Current non-metal nanoparticle-based therapeutic approaches for glioblastoma treatment","volume":"12","author":"Gawel","year":"2024","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.bcp.2025.117276_b0400","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1038\/cddis.2013.388","article-title":"O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0405","doi-asserted-by":"crossref","first-page":"835","DOI":"10.62347\/AERM5603","article-title":"Multifunctional nanoplatforms based on RNA interference for glioma treatment","volume":"15","author":"Zhao","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117276_b0415","unstructured":"F. Chen, et al., Temozolomide Nanoparticles for Targeted Glioblastoma Therapy, 2015."},{"issue":"7","key":"10.1016\/j.bcp.2025.117276_b0420","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/nano11071704","article-title":"Anticancer potential of temozolomide-loaded Eudragit-chitosan coated selenium nanoparticles: In vitro evaluation of cytotoxicity, apoptosis and gene regulation","volume":"11","author":"Mazarei","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bcp.2025.117276_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115174","article-title":"Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy","volume":"165","author":"Krajcer","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.bcp.2025.117276_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-024-04123-2","article-title":"Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study","volume":"14","author":"Hegde","year":"2024","journal-title":"3 Biotech"},{"key":"10.1016\/j.bcp.2025.117276_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0303-5","article-title":"Targeting autophagy to sensitive glioma to temozolomide treatment","volume":"35","author":"Yan","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2025.117276_b0440","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1039\/D0TB00240B","article-title":"Gold nanoparticle-mediated generation of reactive oxygen species during plasmonic photothermal therapy: a comparative study for different particle sizes, shapes, and surface conjugations","volume":"8","author":"Guerrero-Florez","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0445","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/01616412.2015.1133025","article-title":"Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation","volume":"38","author":"Ananta","year":"2016","journal-title":"Neurol. Res."},{"key":"10.1016\/j.bcp.2025.117276_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-017-2324-y","article-title":"Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide","volume":"35","author":"Sharma","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2025.117276_b0455","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejpb.2021.10.007","article-title":"A natural protein based platform for the delivery of temozolomide acid to glioma cells","volume":"169","author":"Helal","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.bcp.2025.117276_b0460","first-page":"325","article-title":"Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas","volume":"20","author":"Wang","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117276_b0465","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.apsb.2022.11.009","article-title":"Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor","volume":"13","author":"Shen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0470","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","article-title":"Emerging role of exosomes in cancer therapy: progress and challenges","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2025.117276_b0475","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400935","article-title":"Mitochondria\u2010Targeted Temozolomide Probe for Overcoming MGMT\u2010Mediated Resistance in Glioblastoma","volume":"26","author":"Szames","year":"2025","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0480","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1038\/s41598-023-31811-5","article-title":"Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models","volume":"13","author":"Gherardini","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0485","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117276_b0490","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.7150\/thno.106081","article-title":"Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment","volume":"15","author":"Roncali","year":"2025","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.bcp.2025.117276_b0495","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.3390\/pharmaceutics14112463","article-title":"Precision nanotoxicology in drug development: current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications","volume":"14","author":"Ahmad","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0500","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer drug discovery based on natural products: from computational approaches to clinical studies","volume":"12","author":"Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bcp.2025.117276_b0505","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/cells14070494","article-title":"Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions","volume":"14","author":"Tang","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117276_b0510","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202410404","article-title":"Nanoparticles designed based on the blood\u2010brain barrier for the treatment of cerebral ischemia\u2010reperfusion injury","author":"Du","year":"2025","journal-title":"Small"},{"issue":"8","key":"10.1016\/j.bcp.2025.117276_b0515","first-page":"2242","article-title":"Organoid models of glioblastoma: advances, applications and challenges","volume":"10","author":"Zhang","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117276_b0520","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.3390\/biomedicines11102743","article-title":"New therapeutic perspectives in prostate cancer: Patient-derived organoids and patient-derived xenograft models in precision medicine","volume":"11","author":"Rago","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117276_b0525","first-page":"1","article-title":"Targeting the glioblastoma resection margin with locoregional nanotechnologies","author":"Kisby","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"02","key":"10.1016\/j.bcp.2025.117276_b0530","article-title":"Nanocarrier-based formulations: Regulatory challenges, ethical and safety considerations in pharmaceuticals","volume":"18","author":"Kardani","year":"2024","journal-title":"Asian J. Pharmaceutics (AJP)"},{"issue":"8","key":"10.1016\/j.bcp.2025.117276_b0535","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11011-024-01414-8","article-title":"Genomic, epigenomic and transcriptomic landscape of glioblastoma","volume":"39","author":"Dakal","year":"2024","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/pharmaceutics13010024","article-title":"Progress of cancer nanotechnology as diagnostics, therapeutics, and theranostics nanomedicine: preclinical promise and translational challenges","volume":"13","author":"Alshehri","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bcp.2025.117276_b0545","first-page":"97","article-title":"Methods for screening and evaluation of antimicrobial activity: a review of protocols, advantages, and limitations","volume":"14","author":"Hossain","year":"2024","journal-title":"Eur. J. MicrobiolImmunol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117276_b0550","doi-asserted-by":"crossref","first-page":"e1976","DOI":"10.1002\/wnan.1976","article-title":"Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy","volume":"16","author":"Sarkar","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117276_b0555","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41578-024-00684-z","article-title":"Engineering nanomaterials for glioblastoma nanovaccination","volume":"9","author":"Hameedat","year":"2024","journal-title":"Nat. Rev. Mater."},{"issue":"11","key":"10.1016\/j.bcp.2025.117276_b0560","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4155\/tde-2022-0035","article-title":"Nanotechnological advancements in the brain tumor therapy: a novel approach","volume":"13","author":"Angolkar","year":"2022","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.bcp.2025.117276_b0565","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yacr.2024.04.009","article-title":"Ferumoxytol-enhanced MRI in brain tumor imaging","volume":"6","author":"Yagmurlu","year":"2024","journal-title":"Adv. Clin. Radiol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T08:30:03Z","timestamp":1761381003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":113,"alternative-id":["S0006295225005416"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117276","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatment","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117276"}}